Praxis Precision Medicines, Inc. (PRAX)
| Market Cap | 9.28B +1,158.1% |
| Revenue (ttm) | n/a |
| Net Income | -326.53M |
| EPS | -13.35 |
| Shares Out | 27.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 457,696 |
| Open | 349.00 |
| Previous Close | 338.07 |
| Day's Range | 317.92 - 353.00 |
| 52-Week Range | 35.18 - 356.00 |
| Beta | 2.78 |
| Analysts | Strong Buy |
| Price Target | 572.13 (+71.67%) |
| Earnings Date | May 7, 2026 |
About PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company’s platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in N... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for PRAX stock is "Strong Buy." The 12-month stock price target is $572.13, which is an increase of 71.67% from the latest price.
News
Praxis Precision Medicines Earnings Call Transcript: Q1 2026
Strong Q1 2026 execution with two NDAs accepted, robust clinical progress, and $1.4B cash position. Commercial launches for ulixacaltamide and Relutrigine are on track, with key study readouts expected in 2026.
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and ...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, tod...
Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, tod...
Praxis Precision price target raised to $437 from $412 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Praxis Precision (PRAX) to $437 from $412 and keeps a Buy rating on the shares.
Praxis Precision announces FDA acceptance of ulixacaltamide NDA
Praxis Precision (PRAX) announced that the FDA has accepted for review its new drug application, or NDA, for ulixacaltamide HCl for the treatment of essential tremor in adults. The FDA
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully int...
Praxis Precision initiated with a Strong Buy at Raymond James
Raymond James last night initiated coverage of Praxis Precision (PRAX) with a Strong Buy rating and $815 price target The firm says the bear thesis on the name “is a
Praxis Precision initiated with a Strong Buy at Raymond James
Raymond James initiated coverage of Praxis Precision (PRAX) with a Strong Buy rating and $815 price target
Praxis Precision announces topline results from EMBRAVE Part A trial
Praxis Precision (PRAX) announced topline results from the EMBRAVE Part A trial of elsunersen in pediatric patients with early-seizure onset SCN2A developmental and epileptic encephalopathy. Elsunerse...
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observe...
Praxis Precision announces FDA acceptance for priority review of relutrigine NDA
Praxis Precision (PRAX) announced that the FDA has accepted for priority review its new drug application for relutrigine, for the treatment of SCN2A and SCN8A developmental and epileptic encephalopath...
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
FDA assigned PDUFA target action date of September 27, 2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous sys...
Praxis Precision Medicines Transcript: TD Cowen 46th Annual Health Care Conference
NDA for Ulyxa submitted with standard review to optimize economic and regulatory outcomes, with launch preparations including disease awareness, specialty pharmacy, and a large sales force. Pipeline progress includes relumitragene for rare epilepsy, vormetragine for focal seizures, and ongoing phase III for elsunersen.
Praxis Precision initiated with an Outperform at Wolfe Research
Wolfe Research initiated coverage of Praxis Precision (PRAX) with an Outperform rating and $500 price target The firm launched coverage of the neuroscience biotech sector with a “portfolio of high
Praxis Precision price target raised to $700 from $500 at Truist
Truist raised the firm’s price target on Praxis Precision (PRAX) to $700 from $500 and keeps a Buy rating on the shares. The company’s Q4 update was “notable” for its
Praxis Precision price target raised to $130 from $95 at Wedbush
Wedbush raised the firm’s price target on Praxis Precision (PRAX) to $130 from $95 and keeps an Underperform rating on the shares. The firm says that most notable in the
Praxis Precision price target raised to $412 from $357 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Praxis Precision (PRAX) to $412 from $357 and keeps a Buy rating on the shares.
Praxis Precision price target raised to $433 from $275 at Baird
Baird raised the firm’s price target on Praxis Precision (PRAX) to $433 from $275 and keeps an Outperform rating on the shares. The firm raised its target as two NDA
Praxis Precision price target raised to $305 from $282 at Wells Fargo
Wells Fargo raised the firm’s price target on Praxis Precision (PRAX) to $305 from $282 and keeps an Equal Weight rating on the shares. The firm recently initiated coverage with
Praxis Precision Medicines Earnings Call Transcript: Q4 2025
Major clinical and regulatory milestones achieved in 2025, including two NDA submissions and strong pivotal data across the CNS portfolio. Financial position strengthened with $1.5B in cash, supporting multiple commercial launches and pipeline progress into 2028.
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S. ...
Praxis Precision Medicines Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Significant unmet need in essential tremor and epilepsy is being addressed with new therapies, with two NDAs on track for mid-February filing. Commercial strategy includes robust sales force, targeted outreach, and pricing in the $40,000–$60,000 range. Cash reserves support launches into 2028.
Praxis Precision price target raised to $800 from $760 at Guggenheim
Guggenheim raised the firm’s price target on Praxis Precision (PRAX) to $800 from $760 and keeps a Buy rating on the shares. The firm’s analysis and feedback from key opinion
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, to...